News Sentiment

MREO sentiment intelligence

Mereo BioPharma Group PLC ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.34 Week of 10 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

74/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.1% over one week, +9.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Mereo BioPharma (MREO) Stock Edges Higher as Biotech Names Find Mixed Footing - Bear Pennant

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 74/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend inactive 9.8% over four weeks
Fair value -85.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 36
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingKey 6
TradingView 6
Stock Titan 6
simplywall.st 5
The National Law Review 2
www.marketscreener.com 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 18
Regulatory and legal 6
Balance sheet 3
Deals and strategy 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
TradingView Direct company coverage

Mereo BioPharma Group plc 1Q 2026: Net loss $(6.7M), EPS $(0.01) — 10-Q Summary

Mereo BioPharma Group plc reported a narrower net loss of $(6.7M) in Q1 2026 compared to $(12.9M) in the prior year, with diluted EPS improving to $(0.01) from $(0.02). The company had no product revenue and is focusing on its late-stage rare disease pipeline, including setrusuma

Tone
Positive 62/100
Event
Earnings
Published
12 May 2026 12:40
Source
TradingView
Stock Titan Direct company coverage

Mereo BioPharma (NASDAQ: MREO) Q1 2026 loss narrows as setrusumab data mixed

Mereo BioPharma announced its Q1 2026 financial results, reporting a narrowed net loss of $6.7 million compared to $12.9 million a year prior, primarily due to reduced general and administrative expenses. While Phase 3 trials for its key drug setrusumab in osteogenesis imperfecta

Tone
Neutral 50/100
Event
Earnings
Published
12 May 2026 12:40
Source
Stock Titan
Stock Titan Direct company coverage

Mereo BioPharma (NASDAQ: MREO) halves Q1 loss and outlines key trial plans

Mereo BioPharma reported a narrower net loss of $6.7 million in Q1 2026, down from $12.9 million year-over-year, mainly due to reduced administrative expenses. The company also provided updates on its rare disease pipeline, noting that while setrusumab's Phase 3 trials missed pri

Tone
Neutral 50/100
Event
Market update
Published
12 May 2026 11:40
Source
Stock Titan